Evidence map›Paper›PMID 39924241›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Anamorelin as a Therapeutic Option for Cancer Cachexia in Advanced Pancreatic Cancer: A Case Report Demonstrating Significant Weight Gain and Quality of Life Improvement.

Motoyasu Kan, Yoshiki Ogane, Kazuki Watabe, Tomoya Takahashi, Miho Sakai, Yu Sekine, Nana Yamada, Chihei Sugihara, Mayu Ouchi, Hiroki Nagashima and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Hallmarks of Cancer Cachexia: Sexual Dimorphism in Related Pathways.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Motoyasu KanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
Yoshiki OganeDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
Kazuki WatabeDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
Tomoya TakahashiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
Miho SakaiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
Yu SekineDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
Nana YamadaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
Chihei SugiharaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
Mayu OuchiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
Hiroki NagashimaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
Koji TakahashiDepartment of Oncology, Graduate School of Medicine, Chiba University, Japan.
Koichiro OkitsuDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
Hiroshi OhyamaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
Izumi OhnoDepartment of Oncology, Graduate School of Medicine, Chiba University, Japan.
Naoya KatoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer cachexia, which is characterized by weight loss and muscle weakness, is common in patients with pancreatic cancer. Anamorelin, a ghrelin receptor agonist, has shown potential for the management of cachexia in various cancers. We herein report a 64-year-old man with unresectable pancreatic cancer who experienced significant weight gain with anamorelin, allowing for continued chemotherapy and an improved quality of life. Despite disease progression, his response suggests the potential utility of anamorelin as a supportive therapy. Cachexia's complex metabolic changes make treatment difficult; however, anamorelin's appetite and weight gain effects highlight its possible role in managing cachexia in pancreatic cancer. Therefore, further research is required in this regard.

Indexed as

CachexiaOligopeptidesPancreatic NeoplasmsQuality of LifeWeight GainHumansHydrazinesMaleMiddle AgedTreatment OutcomeanamorelinHydrazinesOligopeptidesanamorelincancer cahexiaghrelinpancreatic cancersupportive care

Identifiers

PMID39924241
PMCPMC12393967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.